Aging and age-related diseases with a focus on therapeutic potentials of young blood/plasma.
Leila HosseiniParviz ShahabiAli FakhariHamid Soltani ZangbarFatemehsadat SeyedaghamiriJafar SadeghzadehNasrin AbolhasanpourPublished in: Naunyn-Schmiedeberg's archives of pharmacology (2023)
Aging is accompanied by alterations in the body with time-related to decline of physiological integrity and functionality process, responsible for increasing diseases and vulnerability to death. Several ages associated with biomarkers were observed in red blood cells, and consequently plasma proteins have a critical rejuvenating role in the aging process and age-related disorders. Advanced age is a risk factor for a broad spectrum of diseases and disorders such as cardiovascular diseases, musculoskeletal disorders and liver, chronic kidney disease, neurodegenerative diseases, and cancer because of loss of regenerative capacity, correlated to reduced systemic factors and raise of pro-inflammatory cytokines. Most studies have shown that systemic factors in young blood/plasma can strongly protect against age-related diseases in various tissues by restoring autophagy, increasing neurogenesis, and reducing oxidative stress, inflammation, and apoptosis. Here, we focus on the current advances in using young plasma or blood to combat aging and age-related diseases and summarize the experimental and clinical evidence supporting this approach. Based on reports, young plasma or blood is new a therapeutic approach to aging and age-associated diseases.
Keyphrases
- oxidative stress
- chronic kidney disease
- middle aged
- cell death
- cardiovascular disease
- stem cells
- endoplasmic reticulum stress
- gene expression
- mesenchymal stem cells
- climate change
- type diabetes
- ischemia reperfusion injury
- end stage renal disease
- induced apoptosis
- metabolic syndrome
- cell proliferation
- papillary thyroid
- blood brain barrier
- lymph node metastasis
- case control